1. In Vivo
  2. >>Archive

US Has Opportunity To Lead On Ophthalmic Biosimilars

Cardinal Health’s Sonia Oskouei Expands On Findings Of 2022 Biosimilars Report And Acknowledges That Misinformation ‘Continues To Be A Challenge’

 
• By Dave Wallace

With key milestones on the horizon for US biosimilars in 2022 and 2023, Cardinal Health’s vice president of biosimilars, Sonia Oskouei, explains how the industry can best position itself to take advantage of these upcoming opportunities – including potentially a global leadership role in ophthalmology. Oskouei discusses the importance of real-world evidence and education in ensuring confidence in biosimilars, as well as the ongoing struggle against misinformation and the need for clarity over concepts such as interchangeability and unbranded biologics.

Ophtamology
• Source: Alamy

After a gradual ramp-up in the US biosimilars market since the Biologics Price Competition and Innovation Act first created the framework for US biosimilars in 2009, recent years have seen progress accelerate, with several major leaps forward.

Following a boost from a trio of oncology biosimilars – bevacizumab, trastuzumab and rituximab – that were launched by multiple...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By Jo Shorthouse

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.